TAIPEI and CHINO, Calif., April 21, 2026 /PRNewswire/ -- TCM Biotech (TPEx: 4169) has received FDA Breakthrough Device Designation for CatCHimera, a liquid biopsy MRD platform for hepatocellular carcinoma (HCC) that uses HBV–host genome integration junctions — rather than somatic mutations — as tumor-specific circulating biomarkers for post-curative treatment monitoring.
This approach is mechanistically distinct from ctDNA MRD assays currently in the BDD pipeline, which rely on somatic SNVs/indels. CatCHimera leverages the fact that HBV integration sites are unique to each patient's tumor clones, enabling a tumor-informed MRD signal using capture-NGS and ddPCR without mutation calling.
Published and presented clinical data (Hepatology; Cellular and Molecular Gastroenterology and Hepatology; AASLD 2023) include:
- vh-DNA detected in 98% of pre-surgical plasma; detection limit ~1.5 cm
- 158-day mean lead time over CT for recurrence detection
- NPV 92%, PPV 71% for post-operative recurrence
- Combined with AFP + PIVKA-II: 95.8% sensitivity, 95.5% specificity
- Sensitivity superior to AFP alone for tumors <5 cm
HCC remains a blind spot in the MRD landscape — no ctDNA MRD platform has yet pursued BDD for liver cancer, despite HCC being the third leading cause of cancer death globally and having >50% five-year recurrence after resection. Approximately 296 million chronic HBV carriers worldwide define the potential addressable population.
The platform was developed in collaboration with Academician Pei-Jer Chen's group at National Taiwan University and is protected by multi-country patents (US, EU, Singapore, China). TCM's molecular diagnostics laboratory operates under Taiwan Food and Drug Administration (TFDA) LDT accreditation.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-breakthrough-for-first-viral-integration-mrd-liquid-biopsy-in-hcc--new-ctdna-biomarker-class-302748497.html
SOURCE TCM Biotech
